Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, is pleased to announce that it signed a Cannabis Products Supplier Agreement with Medical Cannabis by Shoppers Drug Mart Inc. (“Shoppers”).

The supply agreement with Shoppers includes Simply Bare™ Organic hash, as well as both Wildflower CBD Relief Sticks and Wildflower CBD Cool Sticks in both 30g and 73g product formats. These products will be made available on the Medical Cannabis by Shoppers™ platform.

FolioGrow isn’t a flip-of-the-switch solution—it takes time, standardized processes, and good data to build an AI model for cannabis cultivation.

Agtech, agritech, farmers with self-driving tractors—however you typically refer to it, the agricultural tech industry is expanding quickly. Worth an estimated $17.4 billion in 2019 by a Research and Markets report, it’s projected to more than double by 2027, surpassing $41 billion. 

Artificial intelligence is a key ingredient in the agtech boom. And, increasingly, it’s making its way into the $20+ billion cannabis market. 

Are you thinking about entering the Canadian Cannabis Industry with a micro cultivation operation? Here is part of what you need to know before jumping in.

Micro cultivation licenses were created to support smaller businesses entering the industry, addressing such considerations as smaller budgets and a smaller staff. These licenses allow cultivators to grow up to 200 square meters (2152 sq ft) of cannabis in an approved facility without any limitations on the total amount of cannabis they produce annually.
Like many businesses in Canada, setting up a micro cultivation operation involves working with many levels of government to obtain licenses and permits, a solid business plan, what seems like a ton of capital investment, and plenty of patience!

Cannabinoids overall are likely to be helpful for headache sufferers due to their ability to penetrate the part of the brain involved in migraine pathophysiology.

Did you know that 23 million Americans suffer from severe migraine headaches, and 25% have four or more episodes per month?

In fact, this epidemic costs businesses between 1.2 billion to 17.2 billion dollars annually, through lost productivity and sick time.

In October 2018, Canada became the first G20 country to legalize the recreational use of cannabis. Over the past three years, the province of Ontario — to name just one Canadian jurisdiction — has moved away from having a significantly under-serviced retail market to one that is heavily saturated.

The Cannabis Act (Bill C-45) provided the rules and regulations around the production, distribution, sale and possession of cannabis. However, there are significant differences in each province’s and territory’s retail framework — private, public or hybrid — and the legal age for consumption, purchasing options and personal possession limits.

Top Canadian Marijuana Stocks For Your September 2021 Watchlist

For most of the trading day on September 2nd, marijuana stocks were showing more upward momentum. On this day the cannabis sector was a bit more in the green. This was another moment where investors were able to take some profits after a long decline in the market. Now what investors would like to see is this type of upward trading being more consistent in the sector. Unfortunately, there is no way to give a concrete answer on whether this upward trading will continue. But with more progress continuing outside of the market it may help resonate with positive sentiment amongst other cannabis stocks.

In Badesha v. Cronos Group, 2021 ONSC 4346, the court refused to certify an action alleging securities misrepresentation because there was no reasonable possibility that the alleged misrepresentations caused any loss. The plaintiff argued that thousands of alleged misrepresentations in the defendant’s financial statements should be treated as separate misrepresentations, but failed to establish—or even plead—that anyone relied on any one of them.

There's a very good chance that legal cannabis could be one of the decade's most impressive growth trends.

According to New Frontier Data, the U.S. weed market is on track to grow by an annualized average of 21% through 2025. This would place annual pot sales at north of $41 billion by mid-decade. Meanwhile, cannabis-focused analytics company BDSA expects Canadian weed sales to more than double from $2.6 billion to $6.4 billion between 2020 and 2026. There's plenty of room in these robust growth projections for certain marijuana stocks to thrive.

However, not all pot stocks are going to be winners. Among the veritable sea of fast-growing cannabis stocks are three that should be avoided like the plague in September.

Two Canadian companies are providing a much-needed lifeline to a U.S.-based cannabis retailer in recent deals that would give Thornhill’s Serruya Private Equity and Toronto-based Tilray Inc. an eventual entrypoint into the U.S. cannabis market.

The U.S. is following in Canada’s footprint once again (and why shouldn’t it?) by moving along with steps to legalize and decriminalize cannabis at a federal level. As more and more states are passing legislation to legalize recreational marijuana use with growing support for federal legalization, Canadian companies are working their way into getting a share.Serruya Private Equity is a global private equity firm based in Markham.